A Novel Depot Preparation of Desferrioxamine-B: Development of Formulation Principles

Lowther, Nicholas; Sparks, Kim; Nicklin, Joanne; Jin, Yi

doi:10.1081/ddc-100102283

Cited by 4 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The drug has been assembled in liposomes [109], red cell ghosts [110], or oil vehicle after modifying the molecule to n-decanesulfonate salt [111]. This latter compound reached phase II development in humans but failed to show adequate efficacy [Porter J 1998] 15 .…”

Section: Research Perspectivesmentioning

confidence: 99%

Current Status in Iron Chelation in Hemoglobinopathies

Cappellini¹,

Piga

2008

CMM

View full text Add to dashboard Cite

Although blood transfusions are important for patients with hemoglobinopathies, chronic transfusions inevitably lead to iron overload as humans cannot actively remove excess iron. The cumulative effects of iron overload lead to significant morbidity and mortality, if untreated. Desferrioxamine (DFO) is the reference-standard iron chelator whose safety and efficacy profile has been established through many years of clinical use. DFO side effects are acceptable and manageable however the prolonged subcutaneous infusion regimen of 5-7 days per week is very demanding and results in poor adherence to therapy. Deferiprone (Ferriprox, L1) is a bidentate molecule, orally administrable three-times/day, licensed in Europe and in other regions but in the USA and Canada, for the treatment of iron overload in patients for whom DFO therapy is contraindicated or inadequate. Preliminary evidences suggest that Deferiprone may be more effective than DFO in chelating cardiac iron. The side effects include gastrointestinal symptoms, liver dysfunction, joint pain, neutropenia and agranulocytosis. A weekly assessment of white blood cell counts is recommended because of the risk of agranulocytosis. Deferasirox is a new, convenient, once-daily oral iron chelator that has demonstrated in various clinical trials good efficacy and acceptable safety profile in adult and pediatric patients affected by transfusion-dependent thalassemia major and by different chronic anemias (SCD, BDA, MDS). The long half-life of Deferasirox (16-18 hours) provides sustained 24 hr iron chelation coverage. The efficacy and safety profile have been evaluated in more than 1000 patients in clinical trials allowing FDA registration. Patient satisfaction with Deferasirox was superior than with DFO therapy.

show abstract

Section: Research Perspectivesmentioning

confidence: 99%

Current Status in Iron Chelation in Hemoglobinopathies

Cappellini¹,

Piga

2008

CMM

View full text Add to dashboard Cite

show abstract

“…Considering that this therapy requires a high compromise from the patients, two approaches are being explored: (i) new techniques of DFO administration, and, ii) orally active Fe chelators. DFO administration routes tested include: twice daily subcutaneous bolus injections [54], hydroxyethyl starch DFO [55] and DFO depot [56]. Even when, at least the twice daily subcutaneous bolus injection regimen has shown good results, finding of an orally active Fe chelator is the main objective in this field.…”

Section: Searching For a Better Chelating Agentmentioning

confidence: 99%

Forms of Iron Binding in the Cells and the Chemical Features of Chelation Therapy

Puntarulo

Galleano²

2009

MRMC

View full text Add to dashboard Cite

show abstract

“…Also, improved bioavailability and/or stability of DFO as well as decreased toxicity are observed. Formulations of DFO with n-decanesulfonate or poly(fumaric anhydride-co-sebacic anhydride) produced particles with increased efficiency in chelation treatment by slowing down the release of DFO from the particles [380,381]. In addition, microencapsulated formulations of L1 with Eudragit RS, RL and L90, and cellulose acetate phthalate have been developed to further improve its bioavailability [382].…”

Section: Examination Of Modified Chelators Complexing To Ironmentioning

confidence: 99%

Nanoparticles for the Treatment ofAlzheimer's Disease: Theoretical Rationale, Present Status and Future Perspectives

Liu

Men

Perry

et al. 2003

Nanotechnologies for the Life Sciences

View full text Add to dashboard Cite

The sections in this article are Introduction Rationales: The Ability of Nanoparticles to Cross the BBB – A Useful Tool to Deliver Drugs into the Brain Physiological Functions of the BBB Strategies for Drug BBB Penetration Preparation of Polymeric Nanoparticulate Drug Delivery Systems Possible Mechanisms by which Nanoparticles Cross the BBB Status: Nanoparticle Targeting Transport of Therapeutic Agents for Potential Treatment of AD Nanoparticle Targeting of A β to Deliver Potentially Therapeutic Agents Nanoparticulate Antioxidant Delivery to Increase Efficacy against A β‐mediated Oxidative Stress Nanoparticle Delivery of Copper Chelator for Preventing and Reversing A β Deposition Nanoparticle Transport of Iron Chelators and Metal Chelator Complexes Into and Out of the Brain, Respectively Increased Levels of Various Metals in the Brain of AD Patients Problems with Iron Chelators for Simultaneous Removal of Multimetal Ions for Treatment of AD Nanoparticle Transport Technology to Improve Chelation Therapy for AD Experimental Descriptions Results and Discussion Perspectives Acknowledgments

show abstract

A Novel Depot Preparation of Desferrioxamine-B: Development of Formulation Principles

Cited by 4 publications

References 3 publications

Current Status in Iron Chelation in Hemoglobinopathies

Current Status in Iron Chelation in Hemoglobinopathies

Forms of Iron Binding in the Cells and the Chemical Features of Chelation Therapy

Nanoparticles for the Treatment ofAlzheimer's Disease: Theoretical Rationale, Present Status and Future Perspectives

Contact Info

Product

Resources

About